Gene Silencing, Licensing, Regulation and RNA

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

pharmaphorum

JANUARY 6, 2021

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. In 2019 the Danish company also licensed a preclinical-stage, small-molecule candidate for NASH from Japan’s UBE.

Gene Silencing

Gene Silencing Gene RNA Contract Manufacturing

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. Regulus meanwhile remains a microRNA player, but has suffered a number of setbacks.

Trials

Trials Gene Silencing RNA Gene Expression

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

pharmaphorum

NOVEMBER 24, 2020

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Alnylam licensed inclisiran to The Medicines Company, which was bought last year by Novartis for $9.7

FDA Approval

FDA Approval Gene Silencing Drugs RNA

Clinical Research Informer

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Cash round sets up trial of InteRNA’s microRNA for cancer

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

Stay Connected